Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Parkville Campus, 381 Royal Parade, Parkville, VIC 3052, Australia.
Trials. 2013 May 21;14:148. doi: 10.1186/1745-6215-14-148.
Intensive smoking cessation interventions initiated during hospitalisation are effective, but currently not widely available. Strategies are needed to integrate smoking cessation treatment into routine inpatient care. Pharmacist-led interventions for smoking cessation are feasible and efficacious in both ambulatory and community pharmacy settings. However, there is a lack of evidence from large scale studies of the effectiveness of pharmacist guided programs initiated during patient hospitalisation in achieving long-term abstinence. This study aims to evaluate the effectiveness of a pharmacist-led system change intervention initiated during hospitalisation in Australian public hospitals.
METHODS/DESIGN: A multi-centre, randomised controlled trial will be conducted with 12 months follow-up. Smokers, 18 years or older, will be recruited from the wards of three Victorian public hospitals. Participants will be randomly assigned to a usual care or intervention group using a computer generated randomisation list. The intervention group will receive at least three smoking cessation support sessions by a trained pharmacist: the first during the hospital stay, the second on or immediately after discharge and the third within one month post-discharge. All smoking cessation medications will be provided free of charge during the hospital stay and for at least one week after discharge. Participants randomised to usual care will receive the current care routinely provided by the hospital. All measurements at baseline, discharge, one, six and 12 months will be performed by a blinded Research Assistant. The primary outcome measures are carbon monoxide validated 7-day point prevalence abstinence at six and 12 months.
This is the first large scale study to develop and test a pharmacist-led system change intervention program initiated during patient hospitalisation. If successful, the program could be considered for wider implementation across other hospitals.
ACTRN12612000368831.
住院期间开展强化戒烟干预措施是有效的，但目前尚未广泛应用。需要采取策略将戒烟治疗纳入常规住院护理。药剂师主导的戒烟干预措施在门诊和社区药房环境中都是可行且有效的。然而，在住院期间启动的药剂师指导戒烟计划在实现长期戒烟方面的有效性，缺乏大规模研究的证据。本研究旨在评估在澳大利亚公立医院住院期间启动的药剂师主导的系统改变干预措施的有效性。
方法/设计：将开展一项多中心、随机对照试验，随访时间为 12 个月。将从维多利亚州的三家公立医院的病房招募年龄在 18 岁或以上的吸烟者。参与者将使用计算机生成的随机分配表被随机分配到常规护理或干预组。干预组将由经过培训的药剂师提供至少三次戒烟支持：第一次在住院期间，第二次在出院时或出院后立即，第三次在出院后一个月内。在住院期间和出院后至少一周内，将免费提供所有戒烟药物。随机分配到常规护理组的参与者将接受医院常规提供的现有护理。所有基线、出院、1、6 和 12 个月的测量均由经过盲法的研究助理进行。主要结局指标是在 6 个月和 12 个月时经过一氧化碳验证的 7 天点预存戒烟率。
这是第一项开发和测试在住院期间启动的药剂师主导的系统改变干预计划的大规模研究。如果成功，该计划可能会被考虑在其他医院更广泛地实施。
ACTRN12612000368831。
